Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
McKinsey
Cerilliant
AstraZeneca
Cantor Fitzgerald
Federal Trade Commission
Mallinckrodt
Boehringer Ingelheim
Queensland Health
Johnson and Johnson

Generated: October 20, 2017

DrugPatentWatch Database Preview

Fexofenadine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for fexofenadine hydrochloride and what is the scope of fexofenadine hydrochloride freedom to operate?

Fexofenadine hydrochloride
is the generic ingredient in thirteen branded drugs marketed by Dr Reddys Labs Ltd, Sciegen Pharms Inc, Sanofi Aventis Us, Actavis Mid Atlantic, Wockhardt Ltd, Aurolife Pharma Llc, Teva, Sun Pharm Inds, Barr, Mylan, Hetero Labs Ltd V, Sun Pharma Global, and Impax Pharms, and is included in twenty-five NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fexofenadine hydrochloride has seventy-seven patent family members in forty countries.

There are twenty-three drug master file entries for fexofenadine hydrochloride. One hundred and three suppliers are listed for this compound. There are five tentative approvals for this compound.

Summary for Generic Name: fexofenadine hydrochloride

US Patents:7
Tradenames:13
Applicants:13
NDAs:25
Drug Master File Entries: see list23
Suppliers / Packagers: see list103
Bulk Api Vendors: see list60
Clinical Trials: see list2,333
Patent Applications: see list2,016
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:fexofenadine hydrochloride at DailyMed

Pharmacology for Ingredient: fexofenadine hydrochloride

Tentative approvals for FEXOFENADINE HYDROCHLORIDE

Applicant Application No. Strength Dosage Form
u► Subscribe60/120MGTABLET, EXTENDED RELEASE; ORAL
u► Subscribe30MGTABLET; ORAL
u► Subscribe180MGTABLET; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-010Jan 24, 2011OTCYesYes► Subscribe► SubscribeY► Subscribe
Teva
FEXOFENADINE HYDROCHLORIDE HIVES
fexofenadine hydrochloride
TABLET;ORAL076447-009Apr 13, 2011OTCNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
SUSPENSION;ORAL201373-001Jan 24, 2011OTCYesYes► Subscribe► SubscribeY ► Subscribe
Barr
FEXOFENADINE HYDROCHLORIDE
fexofenadine hydrochloride
TABLET;ORAL076191-003Aug 31, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Sciegen Pharms Inc
FEXOFENADINE HYDROCHLORIDE HIVES
fexofenadine hydrochloride
TABLET;ORAL204507-004Sep 16, 2015OTCNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
FEXOFENADINE HYDROCHLORIDE ALLERGY
fexofenadine hydrochloride
TABLET;ORAL076502-008Apr 12, 2011OTCNoNo► Subscribe► Subscribe► Subscribe
Hetero Labs Ltd V
FEXOFENADINE HYDROCHLORIDE ALLERGY
fexofenadine hydrochloride
TABLET;ORAL204097-002Aug 19, 2016OTCNoNo► Subscribe► Subscribe► Subscribe
Sciegen Pharms Inc
FEXOFENADINE HYDROCHLORIDE ALLERGY
fexofenadine hydrochloride
TABLET;ORAL204507-002Sep 16, 2015OTCNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA HIVES
fexofenadine hydrochloride
SUSPENSION;ORAL201373-002Jan 24, 2011OTCYesYes► Subscribe► SubscribeY ► Subscribe
Teva
FEXOFENADINE HYDROCHLORIDE ALLERGY
fexofenadine hydrochloride
TABLET;ORAL076447-006Apr 13, 2011OTCNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: fexofenadine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-010Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
ALLEGRA HIVES
fexofenadine hydrochloride
TABLET;ORAL020872-009Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-010Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909-002Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA HIVES
fexofenadine hydrochloride
SUSPENSION;ORAL201373-002Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
ALLEGRA HIVES
fexofenadine hydrochloride
TABLET;ORAL020872-009Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-005Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
ALLEGRA
fexofenadine hydrochloride
CAPSULE;ORAL020625-001Jul 25, 1996► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
SUSPENSION;ORAL201373-001Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-005Jan 24, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fexofenadine hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,187,791 Method of providing an antihistaminic effect in a hepatically impaired patient► Subscribe
6,399,632 Method of providing an antihistaminic effect in a hepatically impaired patient► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fexofenadine hydrochloride

Country Document Number Estimated Expiration
JapanH07506828► Subscribe
BrazilPI0619895► Subscribe
Uruguay30021► Subscribe
South Korea101020809► Subscribe
Costa Rica9993► Subscribe
Japan5308824► Subscribe
Spain2121084► Subscribe
Germany69320952► Subscribe
South Korea20080074180► Subscribe
South Africa200803985► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Deloitte
Julphar
Chinese Patent Office
AstraZeneca
Queensland Health
Chubb
Express Scripts
Citi
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot